title: [Cost considerations for whole-body MRI and PET/CT as part of oncologic staging].
abstract: OBJECTIVE
  The aim of this study was to evaluate and discuss economic aspects of whole-body MRI and PET/CT in oncologic staging. Considerations from the perspective of the health care system, the radiologist, and the patients are presented.
  
  
  METHODS
  Costs of both whole-body techniques are compared with the conventional radiologic diagnostic recommendations of the AWFM (Arbeitsgemeinschaft Wissenschaftlich Medizinischer Fachgesellschaften) in oncologic staging of the five most frequent tumor entities. Temporal and monetary aspects are calculated. Invasive, endoscopic, and endosonographic techniques are regarded as essential and cannot be replaced by other techniques. Thus only the minimal potential for cost reduction is quantified.
  
  
  RESULTS
  In the German system there is no cipher to correctly balance whole-body MRI and PET/CT. Using the frequently applied ciphers 5700-5730 and 5378, 5489 (factor 1.0) total costs were 440.45 euros, and adding the cipher for additional series 545.37 euros (60 min examination time) for whole-body MRI and 774.74 euros (879.66 euros) (60/90 min examination time) for whole-body PET/CT. Using the common factor 1.8 costs were 981.66 and 1583.38 euros. On the basis of a simple full cost analysis total costs of whole-body PET/CT were higher than of whole-body MRI by a factor of about 2.0 (about 1123 vs 575 euros). There were substantial monetary and temporal differences between tumor entities. In extended bronchial carcinoma 375.32 euros and 55 min can be saved using whole-body MRI in comparison to conventional recommended techniques and using whole-body PET/CT 88.14 euros and 45 min. In tumor entities of lower stages with thus less essential radiologic diagnostics the potential for cost reduction is substantially lower.
  
  
  CONCLUSIONS
  Whole-body imaging techniques make it possible to reduce the number of necessary separate radiologic examinations and thus time in oncologic staging. A substantial reduction of health care costs seems to be possible in many tumor entities but differences between different tumor entities are decisive.
authors: Abteilung Diagnostische Radiologie, Eberhardt-Karls-Universität Tübingen, Tübingen. christian.plathow@uniklinik-freiburg.de
authors: C
authors: C
authors: Plathow
authors: M
authors: M
authors: Walz
authors: M P
authors: MP
authors: Lichy
authors: P
authors: P
authors: Aschoff
authors: C
authors: C
authors: Pfannenberg
authors: H
authors: H
authors: Bock
authors: S M
authors: SM
authors: Eschmann
authors: C D
authors: CD
authors: Claussen
authors: H P
authors: HP
authors: Schlemmer
mesh_terms: D003953:Diagnosis-Related Groups / Q000191:economics* / Q000706:statistics & numerical data; D005858:Germany / Q000453:epidemiology; D017048:Health Care Costs / Q000706:statistics & numerical data*; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000191:economics* / Q000706:statistics & numerical data; D009367:Neoplasm Staging / Q000191:economics* / Q000706:statistics & numerical data; D009369:Neoplasms / Q000175:diagnosis* / Q000191:economics* / Q000453:epidemiology; D049268:Positron-Emission Tomography / Q000191:economics* / Q000706:statistics & numerical data; D014057:Tomography, X-Ray Computed / Q000191:economics* / Q000706:statistics & numerical data; D051598:Whole Body Imaging / Q000191:economics* / Q000706:statistics & numerical data